* Agouron Pharmaceuticals Inc., of La Jolla, Calif., adopted ashareholder rights plan, but said the move was not a response to atakeover attempt.

* Alanex Corp., of San Diego, will provide Aurora BiosciencesCorp., of La Jolla, Calif., with a set of 150,000 discrete small organiccompounds from its exploratory chemical library for new leadgeneration in Aurora's drug discovery screening systems. Aurora willscreen the library of small molecules against a range of molecular andgenomics targets using its novel fluorescence assays. Aurora andAlanex will share ownership rights to any compounds discovered andwill share any revenues upon commercialization of the compounds.

* Avigen Inc., of Alameda, Calif., has reported a successfulapplication of the company's proprietary adeno-associated virusvector system in the treatment of brain tumors. Avigen researchers, incollaboration with scientists from the department of neurosurgery atNagoya University, in Japan, said they have demonstrated that genetherapy using AAV vectors is effective in treating human braintumors implanted into mice.

* Chiron Corp., of Emeryville, Calif., will partner with BiometricImaging Inc., of Mountain View, Calif., to explore the use ofBiometric Imaging's microvolume fluorometry platform for cellularanalysis. The preferred partnership agreement is a long-termcommitment between the two companies and includes an equityinvestment by Chiron in Biometric Imaging. Financial terms were notdisclosed.

* CoCensys Inc., of Irvine, Calif., has successfully completed the firststage of safety testing with ACEA 1021, its experimental drug forstroke and traumatic brain injury. The compound was well toleratedat doses that resulted in blood levels considerably higher than theblood levels associated with neuroprotection in animal models ofstroke.

* CombiChem Inc., of San Diego, Calif., and Roche Bioscience, ofPalo Alto, Calif., will collaborate on three projects, one each in leadgeneration, lead evolution and lead optimization. Roche Biosciencewill provide research funding and performance-based milestonepayments. Roche Bioscience will retain global developing andmarketing rights and CombiChem will receive royalty payments onmarketed products.

* Cubist Pharmaceuticals Inc., of Cambridge, Mass., said thatunderwriters exercised an option to purchase an additional 375,000shares of common stock to cover over-allotments following thecompany's Oct. 25 initial public offering. All shares will be sold bythe company. UBS Securities LLC, Hambrecht & Quist LLC andPacific Growth Equities Inc. co-managed the offering.

* Eli Lilly and Co., of Indianapolis, Ind., has agreed to manufacturethe finished commercial supply of cyclosporine, produced bySangStat Medical Corp., of Menlo Park, Calif. SangStat will file anapplication with the FDA for marketing clearance by the end of theyear.

* Exocell Inc., of Philadelphia, Pa., has signed an agreement withSummit Pharmaceuticals International Corp., of Tokyo, Japan,licensing exclusive rights to market Glycacor in Japan. Glycacor is adiabetes-management product. Exocell has recently submitted anapplication to the FDA to market Glycacor in the U.S.

* Immunex Corp., of Seattle, said the FDA approved for sale a liquid,multiple-dose form of its white blood cell booster, Leukine. Thedrug, which is granulocyte-macrophage colony stimulating factor, hasbeen on the U.S. market since 1991 for use in restoring white bloodcells destroyed by cancer chemotherapy. Prior to approval of theliquid version, the drug was produced in a powdered form and had tobe reconstituted into a liquid before injection.

* NeXstar Pharmaceuticals Inc., of Boulder Colo., said a Phase IItrial of DaunoXome showed six of 14 non-Hodgkin's lymphomapatients receiving the liposomal form of daunorubicin citrateexperienced a greater than 50 percent reduction in tumor mass. Thepatients had low-grade or intermediate lymphoma. DaunoXomealready is on the market in the U.S., Canada and Europe for AIDS-related Kaposi's sarcoma. In addition to studies for non-Hodgkin'slymphoma, the drug is being evaluated as a treatment for othercancers, such as breast and brain cancers.

* Procept Inc., of Cambridge, Mass., will collaborate with the BritishMedical Research Council, of London, U.K., in the development ofProcept's PRO 2000 antiviral compound as a topical microbicide forthe prevention of HIV infection. The Phase I study will be done inLondon. n

(c) 1997 American Health Consultants. All rights reserved.

No Comments